国产与法国Merieux产伤寒Vi多糖菌苗人体接种反应及血清抗体应答比较

作者对国产伤寒Ｖｉ多糖菌苗和法国Ｍｅｒｉｅｕｘ产伤寒Ｖｉ多糖菌苗人体接种反应及血清抗体应答情况进行比较,接种后６～８小时法国菌苗的体温反应同国产菌苗相比有显著性差异（ｘ２＝５．３４７,０．２５＞Ｐ＞０．０１）,２４小时后反应消失,免后一月国产菌苗和法国菌苗Ｖｉ抗体四倍增长率分别为９１．８０％和８９．６％（ｘ２＝０．１６４,Ｐ＞０．０５）,ＧＭＴ分别为３６．９４和３５．４９（ｔ＝０．６５３,Ｐ＞０．０５）,二者均无显著性差异。     

伤寒Vi多糖菌苗多糖含量及分子大小测定试验

伤寒Ｖｉ多糖菌苗是我国新近研制成功的一种多糖菌苗。为了严格控制该制品的质量,经反复试验,建立了多糖含量和分子大小的测定方法。本文报导了（１）用火箭电泳法测定伤寒Ｖｉ多糖菌苗多糖含量。经对不同实验条件进行比较,选择出较为理想的条件。用该法测定８批样品。结果均符合规程要求。对其中５批样品进行６次重复试验表明,该法的重复性好,操作简单,是测定多糖含量较为理想的方法。（２）用琼脂糖柱层析法对２８批伤寒Ｖｉ多糖菌苗的分子大小进行测定。对用该法所得柱层析收集液分别用Ｈｅｓｔｒｉｎ法和２０６ｎｍ扫描法测定其多糖回收率,对测定结果进行比较。结果表明,两种方法的测定结果无显著性差异（Ｐ＞０．０１）,而且重复性均好。可根据实验室条件选择测定方法。     

伤寒Vi多糖菌苗接种反应观察

本文报告了对我国首次成功的伤寒Ｖｉ多糖菌苗进行人体接种反应观察结果,接种对象为２０至５４岁无伤寒病史,近年无伤寒菌苗接种史的健康人,共６０名,以完全随机的方法分为两组,实验组注射３０μｇＶｉ多糖菌苗,对照组注射Ｖｉ多糖菌苗的稀释液。其结果３０名Ｖｉ多糖菌苗接种者注射后体温无中重反应发生,局部红肿仅有１例中反应。注射后对血压、心律没有影响。红细胞计数,白细胞计数均在正常范围,与接种前相比,无显著差异     

脂多糖对离体培养大鼠血管平滑肌细胞增殖的影响

本研究观察到１０－７～１０－５ｋｇ／Ｌ脂多糖（ｌｉｐｏｐｏｌｙｓａｃｈａｒｉｄｅ,ＬＰＳ）可显著促进血管平滑肌细胞（ＶＳＭＣ）的增殖及ＤＮＡ的合成（Ｐ＜００５）。５×１０－４～１０－３ｋｇ／ＬＬＰＳ却抑制ＶＳＭＣ的增殖及ＤＮＡ的合成,降低其活力（Ｐ＜００１）,并呈时间依赖效应。一氧化氮合酶抑制剂ＮＮｉｔｒｏＬＡｒｇｉｎｉｎｅ（ＬＮＮＡ）可拮抗ＬＰＳ的抑制作用。大剂量ＬＰＳ作用组ＶＳＭＣ上清液中一氧化氮（ＮＯ）代谢产物ＮＯ－３和ＮＯ－２的含量与对照组相比显著增加（Ｐ＜００１）,４８ｈ组比２４ｈ组增加９１％,７２ｈ组比４８ｈ组增加４５％;同时,诱导性一氧化氮合酶（ｉｎｄｕｃｔｉｖｅｎｉｔｒｉｃｏｘｉｄｅｓｙｎｔｈａｓｅ,ｉＮＯＳ）免疫组化染色呈阳性。结果表明,低浓度ＬＰＳ促进ＶＳＭＣ增殖和ＤＮＡ合成,而高浓度ＬＰＳ却明显抑制ＶＳＭＣ增殖和ＤＮＡ合成,降低其活力。这种抑制作用可能与ＬＰＳ诱导ＶＳＭＣ产生的ＮＯ有关。     

被动血凝试验测定伤寒Vi抗体

作者从拘橼酸杆菌中提取纯化获得其Ｖｉ多糖抗原,该抗原具有伤寒沙门氏菌Ｖｉ抗原的免疫学特性,而不含伤寒沙门氏菌０,Ｈ抗原,用其致敏新鲜羊血球作被动血凝试验,特异性敏感性均很好。所需Ｖｉ抗原致敏浓度极低,仅为０．０５ｕｇ／ｍｌ。使用新鲜羊血球凝模式较好,便于观察结果,采用被动血凝试验检测１０６名健康中学生肌肉注射３０ｕｇ伤寒Ｖｉ多糖菌苗前后Ｖｉ抗体的变化情况,发现免疫后血清抗体的四倍增长率达８９％,表明伤寒Ｖｉ多糖苗具有良好的免疫原性。     

TNF—α—IL—1β及LPS对血管平滑肌细胞一氧化氮合酶基因表达的…

通过ＲＮＡ印迹分析和亚硝酸盐含量测定检查ＴＮＦ－α、ＩＬ－１β和ＬＰＳ对大鼠血管平滑肌细胞（ＶＳＭＣ）诱导型一氧化氮合酶基因表达及ＮＯ生成的影响,结果表明,ＴＮＦ－α、ＩＬ－１β和ＬＰＳ均能显诱导ＶＳＭＣｉＳ基因表达和促进ＮＯ生成,其作用强度与浓度和作用时间有关;双因素（ＴＮＦ－α＋ＬＰＳ,ＬＰＳ＋ＩＬ－１β）对诱导ｉＮＯＳ基因表达及ＮＯ生成产生协同作用,ＰｏｌｙｍｙｘｉｎＢ和地塞米松可部分凶制     

甲型副伤寒菌O—特异性多糖与破伤风类毒素结合菌苗的制备 …

以脱毒后去除类脂Ａ的甲型副伤寒杆菌高分子量Ｏ－ＳＰ１和低分子量Ｏ－ＳＰ２为特异笥抗原,以破伤风类毒素（ＴＴ）为蛋白质载体,用已二酸二肼（ＡＤＨ）作为连接剂制备的两种结合物及其多糖免疫ＮＩＨ小鼠,结果显示单独注射Ｏ＿ＳＰ１或Ｏ－ＳＰ２免疫小鼠后,均不能刺激小鼠产生抗ＬＰＳ抗体;而用Ｏ－ＳＰ１－ＴＴ和Ｏ－ＳＰ２－ＴＴ结合物免疫后,小鼠血甭中均产生了特异性抗－ＬＰＳ－ＩｇＧ抗体,且Ｏ－ＳＰ１－ＴＴ免疫组     

TNF-α、IL-1β及LPS对血管平滑肌细胞一氧化氮合酶基因表达的影响及作用机制研究

通过ＲＮＡ印迹分析和亚硝酸盐含量测定检查ＴＮＦ－α、ＩＬ－１β和ＬＰＳ对大鼠血管平滑肌细胞（ＶＳＭＣ）诱导型一氧化氮合酶（ｉＮＯＳ）基因表达及ＮＯ生成的影响．结果表明,ＴＮＦ－α、ＩＬ－１β和ＬＰＳ均能显著诱导ＶＳＭＣｉＮＯＳ基因表达和促进ＮＯ生成,其作用强度与浓度和作用时间有关;双因素（ＴＮＦ－α＋ＬＰＳ,ＬＰＳ＋ＩＬ－１β）对诱导ｉＮＯＳ基因表达及ＮＯ生成产生协同作用．ＰｏｌｙｍｙｘｉｎＢ和地塞米松可部分抑制ＴＮＦ－α对ｉＮＯＳ基因表达的诱导作用及ＮＯ生成     

大鼠肥厚心肌缩短速度和肌凝蛋白重链同功酶谱的变化

用聚丙烯酰胺电泳分离并测定了大鼠左室肌凝蛋白ＡＴＰ酶活性依次降低的同功酶Ｖ_１,Ｖ_２和Ｖ_３的百分比（ＭＩ谱）,从乳头肌力－速度曲线读取心肌最大缩短速度（Ｖ_（ｍａｘ））,观察到：（１）正常大鼠出现增龄性Ｖ_１向Ｖ_３迁移和Ｖ_（ｍａｘ）下降,与８周龄组（Ｓ_０）相比,１６周和２４周龄组（Ｓ_８和Ｓ_（１６））的Ｖ_１／Ｖ_３比,分别下降３８．９％和６１．０％;Ｖ_（ｍａｘ）下降８．３％和１３．３％。（２）高血压肥厚心肌ＭＩ谱的迁移和Ｖ_（ｍａｘ）下降的程度大大超过增龄效应：高血压８周和１６周组（Ｈ_８和Ｈ_（１６））的Ｖ_１／Ｖ_３比值较术前对照Ｓ_０分别下降８４．４％和９３．５％,较同龄假手术对照Ｓ_８和Ｓ_（１６）组也分别低７４．５％和８３．３％,而Ｖ_（ｍａｘ）则比Ｓ_０组下降３３．３％和４８．３％。（３）６组４８只大鼠结果相关分析表明,Ｖ_（ｍａｘ）与Ｖ_１％高度正相关,与Ｖ_３％高度负相关。（Ｐ均小于０．０１）。上述结果提示：高血压肥厚心肌收缩速度明显下降,其主要生化机制似与同功酶谱由Ｖ_１优势向Ｖ_３迁移有关。     

吸附精制百日咳菌苗稳定性的研究

本文对新一代吸附精制百日咳菌苗保存于不同温度条件下的安全和效力稳定性进行了实验,结果表明,９批吸附精制百日咳菌苗经贮存于４～８℃条件下半年、１年、２年和３年后,贮存于常温（１８～２２℃）半年后和贮放于３７℃４０天后,其贮存前后的ＢＷＤＵ／ｍｌ、ＬＰＵ／ｍｌ和ＨＳＵ／ｍｌ间的数值变化,均在制检规程要求的标准数值内,无显著性差异（Ｐ＞０．０５）,说明菌苗的毒性无逆转、菌苗的安全性良好。３批吸附精制百日咳菌苗经贮存于４～８℃条件下７个月和２年后、其贮存前后的效力单位间的数值变化,均在制检规程要求的标准数值内,无显著性差异（Ｐ＞０．０５）,说明菌苗的效力无下降,菌苗的质量稳定。     

Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.

A conjugate vaccine against Salmonella typhi was prepared by covalently binding capsular polysaccharide (Vi) with porin, both isolated from S. typhi. First, Vi and porins were extracted. The Vi was purified from S. typhi Ty2. The purified Vi conformed to the requirements of the World Health Organization. Porins were purified from S. typhi 0901. The Vi was bound to the porins by a heterobifunctional cross-linking reagent, N-succinimidyl-3-(2-pyridyl dithio)-propionate (SPDP). After preparing the Vi-porin conjugate, its protective ability and immunogenicity were studied in mice following systemic immunization. The results showed that the conjugate is 6.5-fold more protective than Vi alone against S. typhi. The mice immunized with conjugate elicited higher anti-Vi antibody (IgG) levels (P < 0.01) than the mice immunized with Vi alone. Anti-porin antibodies were also induced by the conjugate. To study the mucosal immune responses, secretory IgA (sIgA) in the intestinal fluid was measured. Conjugate-immunized mice showed the induction of sIgA as compared to Vi alone. The results showed that when Vi is bound to porins, both isolated from same organism, the resultant conjugate induced both systemic and mucosal immune responses and provided better protection against S. typhi than Vi alone.     

The serological specificities of Salmonella typhi antigens.

Sera prepared with two different strains of Salmonella typhi were analysed against all the soluble antigens isolated from S. typhi 0901, S. typhi Ty2 and S. typhi Vi. Agar-gel diffusion against individual sera showed that, in all the sera, antibodies were induced against somatic antigens and free proteins. Absorptions of the sera with polysaccharides, split from the somatic antigens, removed the antibodies induced against the polysaccharide and its proteinic carrier in most of the somatic antigens of S. typhi 0901. The antibodies left in the absorbed sera reacted against the proteinic moieties of more complex somatic antigens of S. typhi and against free proteins from all the analysed strains. Only the absorption with proteins removed all the precipitating antibodies from the sera. Moreover, in incomplete absorptions with proteins, the first antibodies removed are the antipolysaccharides, since antibodies are never induced against the haptenic polysaccharide but against somatic conjugates; in these the proteinic moiety eventually varies with every batch of bacteria. The sera exhausted of precipitins still agglutinate the bacteria, thus confirming the assumption that agglutinins and precipitins may be different antibodies.     

Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea

The purpose of this study was to evaluate the immunogenicity and safety of Salmonella Typhi Vi capsular polysaccharide vaccine (Vi vaccine) in Korea. The immunogenicity of a single dose of Vi vaccine was evaluated in 157 subjects (75 children and 82 adults) before and at 1, 6, and 12 months after vaccination. Immunogenicity was measured with a passive hemagglutination assay (PHA), quantified as geometric mean titers (GMTs) and seroconversion rates. The safety of the vaccine was investigated by determining adverse reactions occurring within 4 h, 3 days, and 1 month after injection. The seroconversion rate for children and adults 1 month after vaccination was 96.92% and 89.02%, respectively. In the case of children, the GMTs of Vi antibodies before vaccination were 5.87 +/- 1.34 and 142.59 +/- 2.39 at one month after vaccination. For adults, the GMTs before and one month after vaccination were 5.58 +/- 1.28 and 58.56 +/- 3.67, respectively. Vi antibodies persisted for as long as 6 and 12 months after vaccination. All adverse reactions in adults and children were minor and did not require treatment. The Vi CPS vaccine was safe and immunogenic in adults and children older than 5 years.     

Polysaccharides and their common proteinic carrier in the Vi antigens of Citrobacter ballerup and Salmonella typhi Ty2

Immunochemical analysis of Citrobacter ballerup and Salmonella typhi Ty2 showed that the strains share native and heat-resistant proteins that are, apparently, the carriers of a common polysaccharidic determinant present in their respective somatic antigens. After the classic acetic acid hydrolysis, the somatic antigen of C. ballerup reacted, in agar gel, against the homologous antiserum by two precipitation lines, one of which also precipitated against the anti S, typhi Ty2 serum; the hydrolysis of the S. typhi Ty2 somatic antigen demonstrated that, in addition to the 'O' polysaccharide, reacting against all the S. typhi antisera, it contains a polysaccharide that precipitated against the anti-C. ballerup serum. The elusiveness in the agglutinability of only freshly isolated bacterial authorizes some doubt concerning the responsibility of the antipolysaccharide antibodies in the agglutinating Vi sera; in order to induce anitpolysaccharides hyperimmunizations are needed while antiproteins are easily induced by short immunizations.     

肠毒素源性定居因子CS6在减素伤寒沙门氏菌中表达及免疫原性的研究

将编码肠毒素源性大肠杆菌定居因子抗原ＣＳ６基因克隆到ｐＸＬ６７０,转化ａｓｄ基因突变的Ｅ．ｃｏｌｉ Ｘ６０９７,获得重组质粒ｐＳＳ６４,再将后者转化至减毒的△ａｒｏＡ、△ａｒｏＣ、△ａｓｄ伤寒沙门氏菌,构建了无药物抗性且稳定的大肠杆菌和伤寒双价菌苗候选株。小鼠腹腔免疫和攻击实验表明,该菌株对伤寒沙门氏菌毒株的攻击具有良好的保护作用。家兔免疫实验证明,该菌株能产生抗ＣＳ６和伤寒菌Ｖｉ抗原的血清抗体。     

火箭电泳法测定伤寒Vi多糖菌苗多糖含量

伤寒沙门氏菌Ｖｉ抗原系ａ─１,４─Ｎ─乙酰─半乳糖醛酸高度聚合体,其Ｃ２和Ｃ３位分别被Ｎ─乙酰基和０─乙酰基取代,它不能用分光光度法测定其含量,实验表明火箭电泳的火箭峰高与其样品中多糖含量的对数成直线相关关系,作者采用火箭电泳方法对全国六个生物制品研究所的１８批伤寒Ｖｉ多糖菌苗中Ｖｉ多糖含量进行了测定,结果表明多数制品符合规程要求,但部分制品多糖含量偏高,值得引起注意,各所三批制品差别不大,表明各所的生产工艺相对稳定,利用火箭电泳测定伤寒Ｖｉ多糖,操作简单,用时较短,所需样品极少,是目前较为合适的测定伤寒Ｖｉ多糖菌苗多糖含量的方法。     

Complete nucleotide sequence and molecular characterization of ViaB region encoding Vi antigen in Salmonella typhi.

Plasmid pGBM124, which contains a 14-kb Salmonella typhi chromosomal DNA fragment capable of producing the Vi antigen in Escherichia coli HB101 and ViaB-deleted S. typhi GIFU 10007-3, was studied. We determined the complete nucleotide sequence of this fragment and found 11 open reading frames. Mutagenesis, subcloning, and complementation analysis showed that three genes (vipA, vipB, and vipC) are involved in biosynthesis of the Vi polysaccharide. The putative primary amino acid sequence suggests that both vipA and vipB encode the NAD- or NADP-dependent enzymes to synthesize the nucleotide sugar for the Vi polysaccharide. Five genes (vexA, vexB, vexC, vexD, and vexE) may be involved in translocation of the Vi polysaccharide. Proteins VexA, VexB, VexC, and VexD had moderate similarities to components of group II capsule transporters, and the VexC protein had a putative ATP-binding site. These data indicate that the transport system for the Vi polysaccharide belongs to the ATP-binding cassette transporters. By using the isogenic Vi+ and Vi- strains constructed in this study, we reconfirmed that the Vi antigen is necessary for the serum resistance of S. typhi.     

vi—PHA试剂的研制及其在检测伤寒带者中的应用

Purified S. typhi Vi antigen is sensitized with equal volume of tannic acid treated formalational sheep erythrocytes (SRBC) at a final concentration of 1 microgram/ml. The Vi-passive hemagglutination assay (Vi-PHA) diagnostic reagent is developed to detect Vi antibodies to S. typhi for the detection of chronic carriers after typhoid fever and the screening S. typhi healthy carriers from food-handlers, which is characterized with high sensitivity, strong specificity and good stability. This Vi-PHA reagent is able to detect 1.16 micrograms/ml of Vi antibodies and doesn't make any cross reaction with healthy sera. For the sera of other diseases, the cross rate is only 0.84%. Using this reagent, 19 positive sera (6.93%) are detected from 274 convalescent sera from typhoid fever, 14 convalescents of which are stool-culture S. typhi positive, that persists a positive rate of 73.68%; 3 positive sera are detected from 106 foodhandlers, one of which is stool-culture S. typhi positive. Therefore, the reagent is simple, convenient, rapid and easy to be applicated in basic unit.     

Detection of O-acetylated Vi polysaccharide of Salmonella enterica subspecies typhi by enzyme immunoassay.

Immunisation with capsular Vi polysaccharide (Vi PS) of Salmonella enterica serovar Typhi (S. typhi) protects against typhoid. This protection depends on the presence of O-acetyl groups on the Vi PS, which form an immunodominant epitope. An antiserum raised against conjugated Vi PS was used as the basis for an indirect Enzyme Immunoassay (EIA). The antiserum did not react with lipopolysaccharide of five gram negative bacteria including S. typhi. Vi PS from three different sources was tested, and all but one of 18 native Vi PS preparations had EIA values comparable to a standard Vi PS preparation. The sensitivity of the EIA for the detection of O-acetyl groups on Vi PS was compared to an NMR spectroscopy assay (Biologicals 28 (2000) 17-24). The EIA distinguished between O-acetylated and de-O-acetylated Vi PS preparations. However, significantly lower EIA reactivity was observed only for samples which had O-acetylation levels of 25% or less. This assay should facilitate batch control of Vi vaccines.